Brief Report

The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease

  1. Sebastian Paus MD1,*,
  2. Anne Grünewald MS2,
  3. Christine Klein MD2,
  4. Michael Knapp PhD3,
  5. Alexander Zimprich MD4,
  6. Bernd Janetzky MD5,
  7. Jens C. Möller MD6,
  8. Thomas Klockgether MD1,
  9. Ullrich Wüllner MD1

Article first published online: 3 JAN 2008

DOI: 10.1002/mds.21901

Issue

Movement Disorders

Movement Disorders

Volume 23, Issue 4, pages 599–602, 15 March 2008

Additional Information

How to Cite

Paus, S., Grünewald, A., Klein, C., Knapp, M., Zimprich, A., Janetzky, B., Möller, J. C., Klockgether, T. and Wüllner, U. (2008), The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov. Disord., 23: 599–602. doi: 10.1002/mds.21901

Author Information

  1. 1

    Department of Neurology, University of Bonn, Bonn, Germany

  2. 2

    Clinical and Molecular Neurogenetics, Department of Neurology, University of Lübeck, Lübeck, Germany

  3. 3

    Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany

  4. 4

    Hertie-Institute for Clinical Brain Research, Department of Neurology, University of Tübingen, Tübingen, Germany

  5. 5

    Department of Neurology, University of Dresden, Dresden, Germany

  6. 6

    Department of Neurology, University of Marburg, Marburg, Germany

*Department of Neurology, University of Bonn, Sigmund-Freud-Straße 25, Bonn 53105, Germany

Publication History

  1. Issue published online: 26 MAR 2008
  2. Article first published online: 3 JAN 2008
  3. Manuscript Accepted: 18 NOV 2007
  4. Manuscript Revised: 16 NOV 2007
  5. Manuscript Received: 16 AUG 2007

Funded by

  • Federal Ministry of Education and Research
  • German Competence Network on Parkinson's disease, CNP. Grant Numbers: 01G19901, 01GI0201, 01GI0401
  • NGFN. Grant Numbers: 01GS0115, NV-SO2T9
  • BONFOR Program of the University of Bonn (UW)
  • Volkswagen Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (64K)

Keywords:

  • Parkinson's disease;
  • levodopa;
  • DRD2;
  • pharmacogenetics;
  • German Competence Network on PD

Abstract

Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (DRD2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsible for demand of dopaminergic medication, measured in total dopaminergic load per year of disease, in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Regression analysis yielded no significant differences between the TaqIA genotypes. We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD. We propose a practicable system of measuring dopaminergic treatment for future pharmacogenetic studies in PD. © 2007 Movement Disorder Society

View Full Article (HTML) Get PDF (64K)